The challenge of prognostic markers in pleural mesothelioma

被引：6

作者：

Imperatori, Andrea ^{[1
]}

Castiglioni, Massimo ^{[1
]}

Mortara, Lorenzo ^{[2
]}

Nardecchia, Elisa ^{[1
]}

Rotolo, Nicola ^{[1
]}

机构：

[1] Univ Insubria, Ctr Thorac Surg, Dept Surg & Morphol Sci, I-21100 Varese, Italy

[2] Univ Insubria, Dept Biotechnol & Life Sci, I-21100 Varese, Italy

来源：

JOURNAL OF THORACIC DISEASE | 2013年 / 5卷 / 03期

关键词：

Malignant pleural mesothelioma (MPM); prognostic factors; translational research; MALIGNANT MESOTHELIOMA; SERUM; OSTEOPONTIN;

D O I：

10.3978/j.issn.2072-1439.2013.06.12

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Malignant pleural mesothelioma (MPM) is a very aggressive tumor, highly resistant to chemo- and radio-therapy. Treatment of MPM patients is often disappointing, regardless of the modality used. Inter-individual variability of response to multimodal treatment remains a challenge and generally the MPM prognosis continues to be poor. Knowledge of predicting factors of outcome is currently insufficient; therefore, it would be highly desirable to find specific prognostic markers for MPM. Translational research projects are to be implemented.

引用

页码：205 / 206

页数：2

共 16 条

[1]

Cesario A, 2004, LANCET ONCOL, V5, P591, DOI 10.1016/S1470-2045(04)01590-6

[2] Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems [J].

Edwards, JG ;

Abrams, KR ;

Leverment, JN ;

Spyt, TJ ;

Waller, DA ;

O'Byrne, KJ .

THORAX, 2000, 55 (09) :731-735

[3]

Greillier L, 2008, MOL DIAGN THER, V12, P375, DOI 10.2165/1250444-200812060-00004

[4] Incidence and Survival of Malignant Pleural Mesothelioma in Norway A Population-Based Study of 1686 Cases [J].

Helland, Aslaug ;

Solberg, Steinar ;

Brustugun, Odd Terje .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (12) :1858-1861

[5] Multistep renal carcinogenesis in the eker (Tsc 2 gene mutant) rat model [J].

Hino, O .

CURRENT MOLECULAR MEDICINE, 2004, 4 (08) :807-811

[6] Important recent insights into the genetics and biology of malignant pleural mesothelioma [J].

McMillan, Robert ;

Zauderer, Marjorie ;

Bott, Matthew ;

Ladanyi, Marc .

ANNALS OF CARDIOTHORACIC SURGERY, 2012, 1 (04) :462-465

[7] The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma [J].

Mori, Takanori ;

Tajima, Ken ;

Hirama, Michihiro ;

Sato, Tadashi ;

Kido, Kenji ;

Iwakami, Shin-ichiro ;

Sasaki, Shinichi ;

Iwase, Akihiko ;

Shiomi, Kazu ;

Maeda, Masahiro ;

Hino, Okio ;

Takahashi, Kazuhisa .

JOURNAL OF THORACIC DISEASE, 2013, 5 (02) :145-148

[8] Osteopontin is not a specific marker in malignant pleural mesothelioma [J].

Paleari, Laura ;

Rotolo, Nicola ;

Imperatori, Andrea ;

Puzone, Roberto ;

Sessa, Fausto ;

Franzi, Francesca ;

Meacci, Elisa ;

Camplese, Pierpaolo ;

Cesario, Alfredo ;

Paganuzzi, Michela .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2009, 24 (02) :112-117

[9] Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions [J].

Pass, Harvey I. ;

Wali, Anil ;

Tang, Naimei ;

Ivanova, Alla ;

Ivanov, Sergey ;

Harbut, Michael ;

Carbone, Michele ;

Allard, Jeffrey .

ANNALS OF THORACIC SURGERY, 2008, 85 (01) :265-272

[10] Biomarkers and prognostic factors for mesothelioma [J].

Pass, Harvey I. .

ANNALS OF CARDIOTHORACIC SURGERY, 2012, 1 (04) :449-456

← 1 2 →